Abstract
The genomics and proteomics sciences have fundamentally changed the ways in which drug targets are being identified, characterized and validated. Here we review how genomics and proteomics research is improving our understanding of genetic determinants of drug susceptibility and response and, conversely, how organic small molecules mediate their pharmacological effects by modulating genome and proteome activities. We also examine the effect this improved understanding has on the drug discovery and development process.
Keywords: Genomics, proteomics, pharmacogenetics, pharmacogenomics, chemical proteomics, drug resistance, activitybased protein profiling, yeast three-hybrid
Current Drug Targets
Title: Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics
Volume: 7 Issue: 4
Author(s): Gabriele Zybarth and Nikolai Kley
Affiliation:
Keywords: Genomics, proteomics, pharmacogenetics, pharmacogenomics, chemical proteomics, drug resistance, activitybased protein profiling, yeast three-hybrid
Abstract: The genomics and proteomics sciences have fundamentally changed the ways in which drug targets are being identified, characterized and validated. Here we review how genomics and proteomics research is improving our understanding of genetic determinants of drug susceptibility and response and, conversely, how organic small molecules mediate their pharmacological effects by modulating genome and proteome activities. We also examine the effect this improved understanding has on the drug discovery and development process.
Export Options
About this article
Cite this article as:
Zybarth Gabriele and Kley Nikolai, Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics, Current Drug Targets 2006; 7 (4) . https://dx.doi.org/10.2174/138945006776359430
DOI https://dx.doi.org/10.2174/138945006776359430 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-21, miR-106b and miR-375 as Novel Potential Biomarkers for Laryngeal Squamous Cell Carcinoma
Current Pharmaceutical Biotechnology Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry CT-MIBI-SPECT Fusion Imaging Combined with Gamma Probe for Minimally Invasive Radioguided Parathyroidectomy (MIRP)
Current Radiopharmaceuticals Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line
Protein & Peptide Letters Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Current Drug Targets Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?
Clinical Cancer Drugs Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT
Current Cancer Drug Targets Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters HSV Amplicons: Neuro Applications
Current Gene Therapy